Amelioration of the premature ageing‐like features of Fgf‐23 knockout mice by genetically restoring the systemic actions of FGF‐23
- 14 July 2008
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 216 (3), 345-355
- https://doi.org/10.1002/path.2409
Abstract
Genetic ablation of fibroblast growth factor 23 from mice (Fgf‐23−/−) results in a short lifespan with numerous abnormal biochemical and morphological features. Such features include kyphosis, hypogonadism and associated infertility, osteopenia, pulmonary emphysema, severe vascular and soft tissue calcifications, and generalized atrophy of various tissues. To determine whether these widespread anomalies in Fgf‐23−/− mice can be ameliorated by genetically restoring the systemic actions of FGF‐23, we generated Fgf‐23−/− mice expressing the human FGF‐23 transgene in osteoblasts under the control of the 2.3 kb α1(I) collagen promoter (Fgf‐23−/− /hFGF‐23‐Tg double mutants). This novel mouse model is completely void of all endogenous Fgf‐23 activity, but produces human FGF‐23 in bone cells that is subsequently released into the circulation. Our results suggest that lack of Fgf‐23 activities results in extensive premature ageing‐like features and early mortality of Fgf‐23−/− mice, while restoring the systemic effects of FGF‐23 significantly ameliorates these phenotypes, with the resultant effect being improved growth, restored fertility, and significantly prolonged survival of double mutants. With regard to their serum biochemistry, double mutants reversed the severe hyperphosphataemia, hypercalcaemia, and hypervitaminosis D found in Fgf‐23−/− littermates; rather, double mutants show hypophosphataemia and normal serum 1,25‐dihydroxyvitamin D3 levels similar to pure FGF‐23 Tg mice. These changes were associated with reduced renal expression of NaPi2a and 1α‐hydroxylase, compared to Fgf‐23−/− mice. FGF‐23 acts to prevent widespread abnormal features by acting systemically to regulate phosphate homeostasis and vitamin D metabolism. This novel mouse model provides us with an in vivo tool to study the systemic effects of FGF‐23 in regulating mineral ion metabolism and preventing multiple abnormal phenotypes without the interference of native Fgf‐23. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.This publication has 43 references indexed in Scilit:
- The parathyroid is a target organ for FGF23 in ratsJCI Insight, 2007
- Mineral metabolism and aging: the fibroblast growth factor 23 enigmaCurrent Opinion in Nephrology and Hypertension, 2007
- Regulation of fibroblast growth factor-23 in chronic kidney diseaseNephrology Dialysis Transplantation, 2007
- Premature aging in klotho mutant mice: Cause or consequence?Ageing Research Reviews, 2007
- Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient miceMatrix Biology, 2007
- PGC-1β controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosisProceedings of the National Academy of Sciences of the United States of America, 2007
- Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null AnimalsThe American Journal of Pathology, 2006
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolismNature Genetics, 2006
- Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEXOnline Journal of Public Health Informatics, 2003